Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement
- 1 May 2011
- journal article
- Published by Elsevier BV in Thrombosis Research
- Vol. 127 (5), 457-465
- https://doi.org/10.1016/j.thromres.2011.01.001
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacementThrombosis and Haemostasis, 2010
- A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare SettingPharmacoEconomics, 2009
- Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisalHealth Technology Assessment, 2009
- The anticoagulants marketNature Reviews Drug Discovery, 2009
- Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgeryClinical Therapeutics, 2009
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip ArthroplastyNew England Journal of Medicine, 2008
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee ArthroplastyNew England Journal of Medicine, 2008
- Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trialThe Lancet, 2008
- Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trialJournal of Thrombosis and Haemostasis, 2007
- Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trialThe Lancet, 2007